These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30884001)

  • 1. News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure.
    Coats AJS; Seferović PM
    Eur J Heart Fail; 2019 Mar; 21(3):261-263. PubMed ID: 30884001
    [No Abstract]   [Full Text] [Related]  

  • 2. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.
    Januzzi J; Ferreira JP; Böhm M; Kaul S; Wanner C; Brueckmann M; Petrie MC; Ofstad AP; Zeller C; George J; Fitchett D; Zannad F
    Eur J Heart Fail; 2019 Mar; 21(3):386-388. PubMed ID: 30767353
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?
    Pafili K; Papanas N
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):693-695. PubMed ID: 31232616
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.
    Vardeny O; Vaduganathan M
    JACC Heart Fail; 2019 Feb; 7(2):169-172. PubMed ID: 30704605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
    Yamani N; Usman MS; Akhtar T; Fatima K; Asmi N; Khan MS
    Eur J Prev Cardiol; 2020 Apr; 27(6):667-670. PubMed ID: 30966822
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
    Imprialos K; Stavropoulos K; Papademetriou V
    Heart Fail Clin; 2019 Oct; 15(4):519-530. PubMed ID: 31472887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
    Peters MN; Pollock JS; Rajagopalan S
    J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Greene SJ; Butler J
    Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.
    Bassi N; Fonarow GC
    Curr Cardiol Rep; 2018 Sep; 20(11):112. PubMed ID: 30259198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?
    Mishriky BM; Cummings DM; Powell JR
    Diabetes Metab Res Rev; 2024 Jan; 40(1):e3715. PubMed ID: 37649368
    [No Abstract]   [Full Text] [Related]  

  • 14. The bark giving diabetes therapy some bite: the SGLT inhibitors.
    Marshall SM
    Diabetologia; 2018 Oct; 61(10):2075-2078. PubMed ID: 30132029
    [No Abstract]   [Full Text] [Related]  

  • 15. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Butler J; Anker SD
    Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects and Safety of Sodium Glucose Cotransporter 2 Inhibitors in Diabetes Patients With Drug-Refractory Advanced Heart Failure.
    Seo Y; Yamamoto M; Machino-Ohtsuka T; Ishizu T; Aonuma K
    Circ J; 2018 Jun; 82(7):1959-1962. PubMed ID: 29695659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2018 Oct; 72(15):1845-1855. PubMed ID: 30075873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus.
    Jorsal A; Wiggers H; McMurray JJV
    Endocrinol Metab Clin North Am; 2018 Mar; 47(1):117-135. PubMed ID: 29407047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 20. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.